Showing 1 to 1 of 1 results
arabic.euronews.com
🌐 85% Global Worthiness
EMA Conditionally Approves Ocatazil for Relapsed/Refractory ALL
The European Medicines Agency (EMA) conditionally approved Ocatazil, a CAR-T cell therapy, for adults (≥26) with relapsed or refractory acute lymphoblastic leukemia (ALL), based on a Phase 2 trial showing 64% complete response rate (n=113) with a median duration of 14 months; however, serious side e...
EMA Conditionally Approves Ocatazil for Relapsed/Refractory ALL
The European Medicines Agency (EMA) conditionally approved Ocatazil, a CAR-T cell therapy, for adults (≥26) with relapsed or refractory acute lymphoblastic leukemia (ALL), based on a Phase 2 trial showing 64% complete response rate (n=113) with a median duration of 14 months; however, serious side e...
Progress
40% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results